It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALKS’s FA Score shows that 1 FA rating(s) are green whileETON’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALKS’s TA Score shows that 5 TA indicator(s) are bullish while ETON’s TA Score has 4 bullish TA indicator(s).
ALKS (@Pharmaceuticals: Other) experienced а -2.14% price change this week, while ETON (@Pharmaceuticals: Other) price change was +20.65% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +56.20%. For the same industry, the average monthly price growth was -6.16%, and the average quarterly price growth was -6.95%.
ALKS is expected to report earnings on Feb 13, 2025.
ETON is expected to report earnings on Mar 13, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
ALKS | ETON | ALKS / ETON | |
Capitalization | 4.55B | 96.3M | 4,726% |
EBITDA | 519M | -291K | -178,351% |
Gain YTD | 2.199 | 138.813 | 2% |
P/E Ratio | 8.90 | 49.33 | 18% |
Revenue | 1.66B | 31.6M | 5,263% |
Total Cash | 773M | 21.4M | 3,612% |
Total Debt | 372M | 5.4M | 6,886% |
ALKS | ETON | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 30 | 56 | |
SMR RATING 1..100 | 39 | 92 | |
PRICE GROWTH RATING 1..100 | 46 | 34 | |
P/E GROWTH RATING 1..100 | 90 | 6 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ETON's Valuation (90) in the Pharmaceuticals Major industry is in the same range as ALKS (99) in the Biotechnology industry. This means that ETON’s stock grew similarly to ALKS’s over the last 12 months.
ALKS's Profit vs Risk Rating (30) in the Biotechnology industry is in the same range as ETON (56) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew similarly to ETON’s over the last 12 months.
ALKS's SMR Rating (39) in the Biotechnology industry is somewhat better than the same rating for ETON (92) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew somewhat faster than ETON’s over the last 12 months.
ETON's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as ALKS (46) in the Biotechnology industry. This means that ETON’s stock grew similarly to ALKS’s over the last 12 months.
ETON's P/E Growth Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for ALKS (90) in the Biotechnology industry. This means that ETON’s stock grew significantly faster than ALKS’s over the last 12 months.
ALKS | ETON | |
---|---|---|
RSI ODDS (%) | N/A | 2 days ago90% |
Stochastic ODDS (%) | 2 days ago70% | 2 days ago87% |
Momentum ODDS (%) | 2 days ago79% | 2 days ago81% |
MACD ODDS (%) | 2 days ago78% | 2 days ago73% |
TrendWeek ODDS (%) | 2 days ago67% | 2 days ago81% |
TrendMonth ODDS (%) | 2 days ago78% | 2 days ago80% |
Advances ODDS (%) | 10 days ago0% | 5 days ago81% |
Declines ODDS (%) | 8 days ago0% | N/A |
BollingerBands ODDS (%) | 2 days ago69% | 2 days ago83% |
Aroon ODDS (%) | N/A | 2 days ago81% |
A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with VTRS. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then VTRS could also see price increases.
Ticker / NAME | Correlation To ALKS | 1D Price Change % | ||
---|---|---|---|---|
ALKS | 100% | -3.04% | ||
VTRS - ALKS | 34% Loosely correlated | -2.92% | ||
PAHC - ALKS | 26% Poorly correlated | -1.46% | ||
PBH - ALKS | 26% Poorly correlated | +0.57% | ||
COLL - ALKS | 25% Poorly correlated | +0.30% | ||
SEHCF - ALKS | 25% Poorly correlated | N/A | ||
More |
A.I.dvisor tells us that ETON and NBIX have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ETON and NBIX's prices will move in lockstep.
Ticker / NAME | Correlation To ETON | 1D Price Change % | ||
---|---|---|---|---|
ETON | 100% | -1.32% | ||
NBIX - ETON | 22% Poorly correlated | -2.10% | ||
ALKS - ETON | 22% Poorly correlated | -3.04% | ||
PAIOF - ETON | 22% Poorly correlated | N/A | ||
AVDL - ETON | 21% Poorly correlated | -3.58% | ||
ORGO - ETON | 19% Poorly correlated | -9.59% | ||
More |